Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel CARMIL2 mutation.

In conclusion, we found that IL-2 rescued T cell activation and proliferation in CARMIL2-deficient patients. Thus, IL-2 should be further studied as a potential therapeutic modality for these patients.
PMID: 32201938 [PubMed - as supplied by publisher]

Source: Clinical and Developmental Immunology - March 21, 2020 Category: Allergy & Immunology Authors: Shamriz O, Simon AJ, Lev A, Megged O, Ledder O, Picard E, Joseph L, Molho Pessach V, Tal Y, Millman P, Slae M, Somech R, Toker O, Berger M Tags: Clin Exp Immunol Source Type: research